Vaxcyte (NASDAQ: PCVX)
$60.55
(-0.8%)
-$0.48
Price as of April 30, 2024, 4:00 p.m. ET
Vaxcyte Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Vaxcyte Company Info
Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering, and Jeff Fairman on November 27, 2013 and is headquartered in San Carlos, CA.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.